文献速递脑血管病

定量磁共振血管造影筛查与次最大血管成形术治疗症状性椎基底动脉疾病的成本效益

Cost-Effectiveness of Quantitative Magnetic Resonance Angiography Screening and Submaximal Angioplasty for Symptomatic Vertebrobasilar Disease.
PubMed 文献 · Stroke · 2018-01-01

基于VERiTAS研究数据构建30年Markov模型,比较不筛查+标准药物治疗与定量磁共振血管造影筛查+次最大血管成形术两种策略。在6%围手术期卒中风险下,筛查策略平均每例节省0.364个QALY和7312美元终身费用;低流量适合干预患者获益更大(1.485个QALY和21294美元)。作者认为在合适患者中该策略具成本效益,并呼吁开展临床试验评估次最大血管成形术的围手术期风险。

要点

  • 6%围手术期卒中风险下,筛查策略较不筛查平均每例节省0.364个QALY和7312美元。
  • 低流量适合干预患者中,筛查策略平均节省1.485个QALY和21294美元。
  • 筛查获益随围手术期风险升高而下降。

核心结论

  • 在合适患者中,定量磁共振血管造影筛查联合次最大血管成形术(围手术期风险6%)对症状性椎基底动脉闭塞性疾病患者具有QALY和终身费用两方面的成本效益。
  • 作者认为,鉴于潜在的健康和经济节省,有必要开展临床试验评估次最大血管成形术的围手术期风险。

研究设计与样本

  • 构建Markov模型,比较不筛查(仅标准药物治疗)与筛查(定量磁共振血管造影成像并对低椎基底动脉血流可治疗患者行次最大血管成形术)两种策略,时间跨度30年。
  • 卒中与死亡率取自VERiTAS数据,残疾率与费用取自VERiTAS及文献。
  • 以血管成形术围手术期卒中率为主要关注变量进行敏感性分析。

主要发现

  • 在6%围手术期卒中风险下,筛查策略较不筛查策略平均每例节省0.364个QALY,终身费用节省7312美元。
  • 在低流量适合干预的患者中,筛查策略平均节省1.485个QALY,终身费用节省21294美元。
  • 在整个队列中,QALY节省在第一年末出现,经济节省在第6年出现。
  • 围手术期风险越高,筛查的获益下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- The VERiTAS (Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke) study demonstrated posterior circulation distal flow status, determined by quantitative magnetic resonance angiography, is a robust predictor of vertebrobasilar stroke risk in patients with symptomatic atherosclerotic vertebrobasilar disease. Flow-compromised high-risk patients may benefit from flow-restoring endovascular procedures, such as submaximal angioplasty. In this study, we examine the cost-effectiveness of quantitative magnetic resonance angiography screening to identify patients who may benefit from submaximal angioplasty to restore vertebrobasilar flow. Methods- A Markov model was created comparing a no screening strategy with standard medical management alone and a screening strategy involving quantitative magnetic resonance angiography imaging and submaximal angioplasty for treatable patients with low vertebrobasilar flow for a 30-year time horizon. Outcomes included quality-adjusted life years (QALY) and lifetime costs. Rates of stroke and death were obtained from VERiTAS data, and disability rates and costs were derived from VERiTAS and the literature. A sensitivity analysis was performed with periprocedural stroke rate from angioplasty the primary variable of interest. Results- At a 6% periprocedural stroke risk, the screening strategy saved an average of 0.364 QALYs per patient and a lifetime cost savings of $7312 versus the no screening strategy. Among patients with low flow suitable for intervention, the benefit was substantially higher, averaging 1.485 QALYs saved and lifetime cost savings of $21 294. Across the entire cohort, QALY savings were observed at the end of the first year and economic savings at year 6. The benefit of screening declined at higher periprocedural risk. Conclusions- Quantitative magnetic resonance angiography screening and submaximal angioplasty with 6% periprocedural risk in suitable patients are cost effective both in terms of QALY and lifetime costs for patients with symptomatic vertebrobasilar occlusive disease. With potential health and economic savings, a clinical trial examining the periprocedural risk of submaximal angioplasty is warranted. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT00590980.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Esfahani DR, Pandey D, Du X, et al. Cost-Effectiveness of Quantitative Magnetic Resonance Angiography Screening and Submaximal Angioplasty for Symptomatic Vertebrobasilar Disease. Stroke. 2018. PMID: 30012817. doi:10.1161/STROKEAHA.118.022339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。